Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 471 to 480 of 2643 total matches.
Choice of Contraceptives
The Medical Letter on Drugs and Therapeutics • May 15, 2023 (Issue 1676)
failure
rates than other methods (see Table 1). Selection of
a contraceptive method is usually based ...
Intrauterine devices (IUDs) and the etonogestrel
implant are the most effective reversible contraceptive
methods available. Hormonal oral contraceptives,
patches, rings, and injectables are also effective in
preventing pregnancy. When used alone, barrier and
behavioral methods generally have higher failure
rates than other methods (see Table 1). Selection of
a contraceptive method is usually based on patient-specific factors and personal preference
Med Lett Drugs Ther. 2023 May 15;65(1676):73-80 doi:10.58347/tml.2023.1676a | Show Introduction Hide Introduction
Formoterol (Foradil Aerolizer) For Asthma
The Medical Letter on Drugs and Therapeutics • May 14, 2001 (Issue 1104)
dry-powder inhaler 1 inhalation q12h 1 inhalation q12h $70.08
(Novartis) (12 µg/inhalation ...
Formoterol fumarate inhalation powder Foradil Aerolizer, a long-acting beta2-adrenergic receptor agonist, has been approved by the FDA for maintenance treatment of asthma and prevention of exercise-induced bronchospasm. The drug has been available in Europe for many years.
FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021 (Issue 1615)
43,548 subjects ≥16 years old were randomized 1:1
to receive 30 mcg of the Pfizer-BioNTech vaccine ...
The FDA has issued an Emergency Use Authorization
(EUA) for the Pfizer-BioNTech mRNA-based vaccine
for prevention of COVID-19 in persons ≥16 years old.
Opdualag for Metastatic Melanoma (online only)
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023 (Issue 1668)
checkpoint inhibitors — nivolumab (Opdivo),
a programmed death receptor-1 (PD-1) inhibitor, and
relatlimab ...
Opdualag (BMS), a fixed-dose combination of two
immune checkpoint inhibitors — nivolumab (Opdivo),
a programmed death receptor-1 (PD-1) inhibitor, and
relatlimab-rmbw, a lymphocyte-activation gene-3
(LAG-3) blocking antibody — has been approved by
the FDA for treatment of unresectable or metastatic
melanoma in patients ≥12 years old. Relatlimab, which
is only available in combination with nivolumab, is
the first LAG-3 blocking antibody to become available
in the US. Immune checkpoint inhibitors, including
the anti-CTLA-4 antibody ipilimumab (Yervoy) and
the PD-1 inhibitors...
Med Lett Drugs Ther. 2023 Jan 23;65(1668):e19-20 doi:10.58347/tml.2023.1668g | Show Introduction Hide Introduction
Azithromycin Extended-Release (Zmax) for Sinusitis and Pneumonia
The Medical Letter on Drugs and Therapeutics • Sep 28, 2005 (Issue 1218)
DAILY
DRUG DOSAGE COST
1
Azithromycin, immediate-release tablets
Zithromax ...
Zmax (Pfizer), an extended-release oral suspension of azithromycin, has been approved by the FDA for single dose treatment of mild to moderate community acquired pneumonia (CAP) and acute bacterial sinusitis (ABS) in adults. Immediate-release azithromycin will probably become available generically later this year when its patent expires.
Penmenvy — A Second Pentavalent Meningococcal Vaccine
The Medical Letter on Drugs and Therapeutics • Apr 14, 2025 (Issue 1726)
in the US; Penbraya was licensed in 2023.1
MENINGOCOCCAL DISEASE — Six serogroups of
N. meningitidis (A, B, C, W, X ...
The FDA has licensed the pentavalent vaccine
Penmenvy (GSK) for prevention of invasive
meningococcal disease caused by Neisseria
meningitidis serogroups A, B, C, W, or Y (MenABCWY)
in persons 10-25 years old. Penmenvy is the second
pentavalent meningococcal vaccine to become
available in the US; Penbraya was licensed in 2023.
Med Lett Drugs Ther. 2025 Apr 14;67(1726):57-9 doi:10.58347/tml.2025.1726a | Show Introduction Hide Introduction
Aliskiren (Tekturna) for Hypertension
The Medical Letter on Drugs and Therapeutics • Apr 09, 2007 (Issue 1258)
to increase
plasma renin activity (PRA) because it binds renin with
high affinity in plasma.
1,2
In one ...
Aliskiren (ah LIS ker in; Tekturna - Novartis), the first direct renin inhibitor, has been approved by the FDA for treatment of hypertension. It is indicated for oral use either as monotherapy or in combination with other antihypertensive agents.
Trimethoprim-Polymyxin B for Bacterial Conjunctivitis
The Medical Letter on Drugs and Therapeutics • Jul 27, 1990 (Issue 823)
of trimethoprim sulfate 0.1% with polymyxin B sulfate 10,000
units/ml (Polytrim − Burroughs Wellcome, distributed ...
Bacterial infections of the conjunctivae are usually self-limited, but topical antimicrobial therapy can be helpful. A solution of trimethoprim sulfate 0.1% with polymyxin B sulfate 10,000 units/ml (Polytrim - Burroughs Wellcome, distributed by Allergan) was recently marketed in the USA for treatment of superficial ocular bacterial infections.
In Brief: Auvi-Q Epinephrine Auto-Injector for Infants and Toddlers
The Medical Letter on Drugs and Therapeutics • May 21, 2018 (Issue 1547)
epinephrine autoinjector
(Auvi-Q 0.1 mg – Kaléo) for emergency treatment
of anaphylaxis in children weighing ...
The FDA has approved a lower-dose epinephrine auto-injector (Auvi-Q 0.1 mg – Kaléo) for emergency treatment of anaphylaxis in children weighing 7.5-15 kg (16.5-33 lbs). It is the first epinephrine auto-injector to be approved for use in infants and toddlers weighing less than 15 kg. Previously, Auvi-Q and other epinephrine auto-injectors were only available in 0.15- and 0.3-mg strengths for patients weighing 15-30 kg or ≥30 kg, respectively.The recommended dose of epinephrine for intramuscular (IM) or subcutaneous (SC) administration is 0.01 mg/kg. None of the previously available...
COVID-19 Update: Metformin to Prevent Long Covid?
The Medical Letter on Drugs and Therapeutics • May 29, 2023 (Issue 1677)
ward
than in those who did not (43.1% and 27.5% vs 5.7%).
It was most prevalent in adult females.1 ...
Results from a double-blind trial suggest that off-label
use of the oral antihyperglycemic drug metformin
in patients with COVID-19 may decrease the risk
of post-acute sequelae of SARS-CoV-2 infection
("long COVID").
Med Lett Drugs Ther. 2023 May 29;65(1677):87-8 doi:10.58347/tml.2023.1677e | Show Introduction Hide Introduction
